A randomized controlled trial for patients with unresectable stage III NSCLC with EGFR mutations showed that, compared to chemotherapy combined with RT, erlotinib combined with TRT achieved a median PFS of 24.5 months (14). Here, EGFR is linked to non-small cell lung carcinoma.